Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response

Gut

Volumn 53, Issue 1, 2004, Pages 91-98

  Furrie, E ^a   Macfarlane, S ^a   Cummings, J H ^a   Macfarlane, G T ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; MEMBRANE ANTIGEN;

ADULT; AGED; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ARTICLE; BACTERIAL COLONIZATION; CELL RESPIRATION; CONTROLLED STUDY; CROHN DISEASE; FEMALE; HUMAN; HUMAN TISSUE; INTESTINE BIOPSY; INTESTINE FLORA; INTESTINE MUCOSA; MALE; NEUTROPHIL CHEMOTAXIS; OPSONIZATION; PRIORITY JOURNAL; RESPIRATORY BURST; ULCERATIVE COLITIS;

AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; ANTIGENS, SURFACE; BACTERIA; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTESTINAL MUCOSA; MALE; MIDDLE AGED; NEUTROPHILS; RECTUM; RESPIRATORY BURST;

EID: 0347867358     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.53.1.91     Document Type: Article

References (62)

1. Podolsky DK. Inflammatory bowel disease (First of two parts). N Engl J Med 1991;325:928-37.
2. Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet 2002;359:331-40.
3. Macdonald TT, Monteleone G, Pender SLF. Recent developments in the immunology of inflammatory bowel disease. Scand J Immunol 2000;51:2-9.
4. McAlindon ME, Gray T, Galvin A, et al. Differential lamina propia cell migration via basement membrane pores of inflammatory bowel disease mucosa. Gostroenterology 1998;115:841-8.
5. Campieri M, Gionchetti P. Bacteria as the cause of ulcerative colitis. Gut 2001;48:132-5.
6. Schultsz C, Van Den Berg FM, Ten Kate FW, et al. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology 1999;117:1089-97.
7. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991;67:1033-6.
8. Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995;102:448-55.
9. Elson CO, Sartor RB, Tennyson GS, et al. Experimental models of inflammatory bowel disease. Gastroenterology 1995;109:1344-67.
10. Ehrhardt RO, Ludviksson BR, Gray B, et al. Induction and prevention of colonic inflammation in IL-2-deficient mice. J Immunol 1997;158:566-73.
11. Bhan AK, Mizoguchi E, Neal Smith R, et al. Colitis in transgenic and knockout animals as models of human inflammatory bowel disease. Immunol Rev 1999;169:195-207.
12. Onderdonk AB, Richardson JA, Hammer RE, et al. Correlation of fecal microflora of HLA-B27 transgenic rats with inflammatory bowel disease. Infect Immun 1998;66:6022-3.
13. Rath HC, Herfarth HH, Ikeda JS, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colonic, gastric, and systemic inflammation in HLA-B27/hb2m transgenic rats. J Clin Invest 1996;98:945-53.
14. Rath HC, Schultz M, Freitag R, et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats. Infect Immun 2001;69:2277-85.
15. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for the development of spontaneous colitis and immune system activation in IL-10 deficient mice. Infect Immun 1998;66:5224-31.
16. Sadlack B, Merz H, Schorle H. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:253-61.
17. Taurog JD, Richardson JA, Croft JT, et al. The germ free state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994;180:2359-64.
18. Kett K, Rognum TO, Brandtzaeg P. Mucosal subclass distribution of immunoglobulin G-producing cells is different in ulcerative colitis and Crohn's disease of the colon. Gostroenterology 1987;93:919-24.
19. Dunn-Walters DK, Boursier L, Hackett M, et al. Biased JH. usage in plasma cell immunoglobulin gene sequences from colonic mucosa in ulcerative colitis but not in Crohn's disease. Gut 1999;44:382-6.
20. Thoree VC, Golby SJC, Boursier L, et al. Related IgA1 and IgG producing cells in blood and diseased mucosa in ulcerative colitis. Gut 2002;51:44-50.
21. Ravetch JV, Clynes RA. Divergent roles for Fc receptors and complement in vivo. Ann Rev Immunol 1998;16:421-32.
22. Grisham MB. Oxidants and free radicals in inflammatory bowel disease. Lancet 1994;344:859-61.
23. Beckman JS, Beckman TW, Chen J, et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 1990;87:1620-4.
24. Shiratora Y, Aoki S, Takada H, et al. Oxygen-derived free radical generating capacity of polymorphonuclear cells in patients with ulcerative colitis. Digestion 1989;44:163-71.
25. Simmonds NJ, Allen RE, Stevens TR, et al. Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology 1992;103:186-96.
26. McKenzie SJ, Baker MS, Buffinton GD, et al. Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease J Clin Invest 1996;98:136-41.
27. Hodgson HJ, Potter BJ, Skinner J, et al. Immune complex mediated colitis in rabbits. An experimental model. Gut 1978;19:225-32.
28. Israel EJ, Taylor S, Wu Z, et al. Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells. Immunology 1997;92:69-74.
29. Dickinson BL, Badizadegan K, Wu Z, et al. Bidirectional FcRn-dependent IgG transport in a polerised human intestinal epithelial cell line. J Clin invest 1999;104:903-11.
30. Saxon A, Shanahan F, Londers C, et al. Distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allerg Clin Immunol 1990;86:202-21.
31. Snook JA, Lowes JR, Wu KC, et al. Serum and tissue autoantibodies to colonic epithelium in ulcerative colitis. Gut 1991;32:163-6.
32. Seibold F, Brandwein S, Simpson S, et al. pANCA represents a cross-reactivity to enteric bacterial antigens. J Clin Immunol 1998;18:153-60.
33. Cohavy O, Bruckner D, Gordon LK, et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun 2000;68:1542-8.
34. Wei B, Harnisha D, Gordon LK, et al. Molecular cloning of a Bacteroides caccae TonB-linked outer membrane protein identified by an inflammatory bowel disease marker. Infect Immun 2001;69:6044-54.
35. Khoo UY, Bjarnason I, Donaghy A, et al. Antibodies to colonic epithelial cells from the serum and colonic washings in ulcerative colitis. Gut 1995;37:63-70.
36. Dickinson RJ, O'Connor HJ, Pinder I, et al. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gyt 1985;26:1380-4.
37. Mantzaris GJ, Hatzis A, Kontogiannis P, et al. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1994;89:43-6.
38. Turunen UM, Farkkila MA, Hakala K, et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 1998;115:1072-8.
39. Present DH. Ciprofloxacin as a treatment for ulcerative colitis - not yet. Gostroenterology 1998;115:1289-91.
40. Cummings JH, Macfarlane GT. Is there a role for microorganisms? In: Jewell DP, Warren BF, Mortensen NJ, eds. Challenges in inflammatory bowel disease. Oxford: Blackwell Science, 2001:47-8.
41. Matsuda H, Fujiyama Y, Andoh A, et al. Characterisation of antibody responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis. J Gastroenterol Hepatol 2000;15:61-8.
42. Hartley MG, Hudson MJ, Swarbrick ET, et al. The rectal mucosa associated microflora in patients with ulcerative colitis. J Med Microbiol 1992;36:96-103.
43. Poxton IR, Brown R, Sawyer A, et al. Mucosa-associated bacterial flora in the human colon. J Med Microbiol 1997;46:85-91.
44. Macpherson A, Khoo UY, Forgacs I, et al. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996;38:365-75.
45. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44-54.
46. Macfarlane GT, Hay S, Macfarlane S. Effect of different carbohydrates on growth, polysaccharidase and glycosidase production by Bacteroides ovatus, in batch and continuous culture. J Appl Bacteriol 1990;68:179-87.
47. Beerens H. An elective and selective isolation medium for Bifidobacterium spp. Lett Appl Bacteriol 1990;11:155-7.
48. Macfarlane GT, Cummings JH, Allison C. Protein degradation by human intestinal bacteria. J Gen Microbiol 1986;132:1647-56.
49. Macfarlane S, Quigley ME, Hopkins MJ, et al. Effect of retention time on polysaccharide degradation by mixed populations of human colonic bacteria studied under multi-substrate limiting conditions in a three-stage compound continuous culture system. FEMS Microbiol Ecol 1998;26:231-43.
50. Ducluzeau R. Role of experimental microbial ecology in gastroenterology. In: Bergogne-Benezin, ed. Microbial ecology and intestinal infections. Paris: Springer-Verlag, 1989:7-26.
51. Fahlgren A, Hammarstrom S, Danielsson A, et al. Increased expression of anti-microbial peptides and lysozyme in colonic epithelial cells or patients with ulcerative colitis. Clin Exp Immunol 2003;131:90-101.
52. Gouni-Berthold I, Baumeister B, Berthold HK, et al. Immunoglobulins and IgG subclasses in patients with inflammatory bowel disease. Hepatogastroenterology 1999;46:1720-3.
53. Mombaerts P, Mizoguchi E, Grusby MJ, et al. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 1993;75:274-82.
54. Mizoguchi A, Mizoguchi E, Tonegawa S, et al. Alteration of a polyclonal to an oligoclonal immune response to cecal aerobic bacterial antigens in TCRα mutant mice with inflammatory bowel disease. Int Immunol 1996;8:1387-94.
55. Andre C, Andre F, Fargier C. Distribution of IgA1 and IgA2 plasma cells in various normal human tissues and in the jejunum of plasma IgA-deficient patients. Clin Exp Immunol 1978;33:327-31.
56. Salmi M, Kalimo K, Jalkanen S. Induction and function of vascular adhesion protein-1 at sites of inflammation. J Exp Med 1993;178:2255-60.
57. Salmi M, Granfors K, MacDermott R, et al. Aberrant binding of lamina propria lymphocytes to vascular endothelium in inflammatory bowel disease. Gastroenterology 1994;106:596-605.
58. Snook JA, De Silva HJ, Jewell DP. The association of autoimmune disorders with inflammatory bowel disease. Q J Med 1989,72:835-40.
59. Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae monnan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998;42:788-91.
60. Ibnou-Zekri N, Blum S, Schiffrin EJ, et al. Divergent patterns of colonization and immune response elicited from two intestinal lactobaccilus strains that display similar properties in vitro. Infect Immun 2003;71:428-36.
61. Bridger S, Lee JCW, Bjarnason I, et al. In siblings with similar genetic susceptibility for inflammatory bowel disease, smokers tend to develop Crohn's disease and non-smokers develop ulcerative colitis. Gut 2002;51:21-5.
62. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22.